Verastem Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
33.8%projected annual EPS growth
Analyst Coverage
8analysts covering
FY Revenue (est.)
$116.4Mnext fiscal year
FY EPS (est.)
-$1.80next fiscal year
Monitoring Framework
Key Performance Indicators
Net Product Revenue Quarterly18.7MTarget: LGSOC franchise self-sustaining in H2 2026
Cash, Cash Equivalents, and Investments Quarterly181.7MTarget: Sufficient cash runway into H1 2027
RAMP 205 Confirmed Objective Response Rate (cORR) Annually52.0%Target: Maintain competitive efficacy vs. peers
Watch Items
- VS-7375 TARGET-D Clinical Program ProgressTrigger: Dosing of first patients in TARGET-D 202 and TARGET-D 203 trialsAction: Evaluate initial safety, tolerability, and efficacy data from Phase 2 trials to confirm best-in-class potential.
- Going Concern and Cash Burn RateTrigger: Cash runway falling below 12 months due to Phase 2 trial expensesAction: Assess potential strategic collaborations, licensing deals, or equity financing to extend the cash runway.
- NDA Submission for Avutometinib plus Defactinib in LGSOCTrigger: FDA feedback on the final data package by end of 2026Action: Prepare and submit the New Drug Application (NDA) for recurrent low-grade serous ovarian cancer.
Research as of 19 Jun 2026